Recent compelling evidence has suggested that the glutamate system is a primary mediator
of psychiatric pathology and also a target for rapid-acting antidepressants. Clinical research
in mood and anxiety disorders has shown alterations in levels, clearance, and metabolism of
glutamate and consistent volumetric changes in brain areas where glutamate neurons
predominate. In parallel, preclinical studies with rodent stress and depression models have
found dendritic remodeling and synaptic spines reduction in corresponding areas …